Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER3-DXd + Osimertinib in EGFR-mutated NSCLC
NCT04676477Phase 1Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2021
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, randomised, open-label trial of patritumab deruxtecan in non-small cell lung cancer (NSCLC) (6 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Dose-limiting Toxicities up to 40 days, Treatment-emergent Adverse Events up to 18 months and 3 more. Started Jun 2021; status: active, not recruiting.
02
Drugs
patritumab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04676477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04676477.